Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 5:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Glucan II Clear all
Completed Phase 1Phase 2 Interventional Results available

Metformin to Augment Low Milk Supply (MALMS) Study

NCT02179788
View directory record Official record
Conditions
Low Milk Supply, Pre-diabetes, Insulin Resistance, Suppressed Lactation
Interventions
Standard care, Metformin, Placebo
Behavioral · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
20 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 7, 2026, 5:09 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery

NCT03276026
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Respiratory Conditions Due to Other External Agents
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
Virtua Health, Inc.
Other
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Mount Holly, New Jersey
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Sep 7, 2026, 5:09 PM EDT
Completed Phase 2 Interventional

Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment

NCT00089258
View directory record Official record
Conditions
Neuroblastoma
Interventions
beta-glucan, monoclonal antibody 3F8, sargramostim, isotretinoin
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Sep 7, 2026, 5:09 PM EDT
Recruiting Phase 2 Interventional

A Clinical Trial of Soluble Fiber for Asthma

NCT06372249
View directory record Official record
Conditions
Asthma in Children
Interventions
Inulin
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 7, 2026, 5:09 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Multi-Center, Prospective, Randomized, Comparison of AWBAT™-D vs. Xeroform™ or Glucan II™ for Treatment of Donor Sites in Burn Surgery

NCT00964470
View directory record Official record
Conditions
Treatment of Donor Site Burns
Interventions
AWBAT™-D and XEROFORM™ OR GLUCAN II™ dressings
Device
Lead sponsor
Aubrey Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
3
States / cities
Indianapolis, Indiana • Cincinnati, Ohio • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 21, 2010 · Synced Sep 7, 2026, 5:09 PM EDT
Terminated No phase listed Observational

A Randomized Comparison Study of Aquacel Ag and Glucan II as Donor Site Dressings

NCT00581217
View directory record Official record
Conditions
Burns
Interventions
Aquacel Ag, Glucan II
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Sep 7, 2026, 5:09 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)

NCT03850964
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia, Nosebleed, HHT
Interventions
Pazopanib, Placebo oral capsule
Drug
Lead sponsor
Cure HHT
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 7, 2026, 5:09 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors

NCT03781778
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, Cancer Survivor, Colorectal Adenocarcinoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8
Interventions
Dietary Intervention (resistant starch), Dietary Intervention (regular starch), Questionnaire Administration
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 7, 2026, 5:09 PM EDT
Withdrawn Phase 2 Interventional

Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma

NCT04995094
View directory record Official record
Conditions
Pathologic Stage III Cutaneous Melanoma AJCC v8
Interventions
Imprime PGG, Pembrolizumab
Biological
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
La Jolla, California • Whittier, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 7, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

NCT00129259
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
Biological · Other · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 30 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Sep 7, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women

NCT01290315
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferric Carboxymaltose (FCM), Iron Sucrose / Iron Dextran
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 7, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Inulin for Infections in the Intensive Care Unit

NCT03865706
View directory record Official record
Conditions
Antibiotic Resistant Infection, Nosocomial Infection, Pathogen Transmission, Nutrition Disorders, Critical Illness, Sepsis
Interventions
Inulin Oral Suspension, Placebo Oral Suspension, Broad-spectrum antibiotics
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Sep 7, 2026, 5:09 PM EDT
Not listed Phase 2 Interventional

Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

NCT00002099
View directory record Official record
Conditions
HIV Infections
Interventions
Lentinan, Didanosine
Drug
Lead sponsor
AJI Pharma USA
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 7, 2026, 5:09 PM EDT
Recruiting Phase 2 Interventional

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

NCT06057948
View directory record Official record
Conditions
Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma
Interventions
OPT-821 (QS-21), oral β-glucan
Biological · Dietary Supplement
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 7, 2026, 5:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

NCT06866262
View directory record Official record
Conditions
Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Inulin, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration
Procedure · Dietary Supplement · Biological + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 7, 2026, 5:09 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

NCT01470118
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
alcaftadine 0.25% ophthalmic solution, olopatadine 0.2% ophthalmic solution, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
10 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Sep 7, 2026, 5:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

NCT01269385
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Interventions
alemtuzumab, rituximab, PGG beta-glucan, flow cytometry, laboratory biomarker analysis, DNA analysis, fluorescence in situ hybridization, polymerase chain reaction, polymorphism analysis, mutation analysis
Biological · Drug · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Sep 7, 2026, 5:09 PM EDT
Suspended Phase 1Phase 2 Interventional

Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

NCT01562626
View directory record Official record
Conditions
Tumors, Neoplasms, Cancer
Interventions
APS001F, Flucytosine (5-FC), 10% maltose
Drug
Lead sponsor
Anaeropharma Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
2
States / cities
Minneapolis, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Sep 7, 2026, 5:09 PM EDT
Completed Phase 1 Interventional

A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC)

NCT00001009
View directory record Official record
Conditions
HIV Infections
Interventions
Dextran sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 7, 2026, 5:09 PM EDT
Terminated Phase 2 Interventional Results available

Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)

NCT00290407
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, Lymphoma, Small Lymphocytic
Interventions
Rituximab, Beta-Glucan
Drug · Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Sep 7, 2026, 5:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit

NCT02863809
View directory record Official record
Conditions
Keratolysis
Interventions
Riboflavin, Dextran, UVA Light Source
Drug · Device
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 7, 2026, 5:09 PM EDT
Completed Phase 1 Interventional

Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

NCT00002098
View directory record Official record
Conditions
HIV Infections
Interventions
Lentinan, Didanosine
Drug
Lead sponsor
AJI Pharma USA
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Francisco, California • Maitland, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 7, 2026, 5:09 PM EDT
Terminated Not applicable Interventional

MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer

NCT03461354
View directory record Official record
Conditions
Mucositis Oral, Head and Neck Cancer
Interventions
MucoLox, Sodium Bicarbonate
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 7, 2026, 5:09 PM EDT
Completed Phase 4 Interventional Results available

Optimizing Post-operative Recovery in Bariatric Patients With Obstructive Sleep Apnea Undergoing Outpatient Surgery: A Comparison of Sugammadex and Neostigmine

NCT04570150
View directory record Official record
Conditions
Anesthesia
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2024 · Synced Sep 7, 2026, 5:09 PM EDT